Journal of the European Academy of Dermatology and Venereology

Article	Citations
Cutaneous manifestations in COVID‐19: a first perspective	690
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children	207
Vascular skin symptoms in COVID‐19: a French observational study	188
Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients	177
Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life	158
Urticarial eruption in COVID‐19 infection	157
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)	153
2020 European guideline on the management of syphilis	148
Cutaneous manifestations in COVID‐19: a new contribution	141
Onychomycosis: a review	140
Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience	138
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations	134
Acral cutaneous lesions in the time of COVID‐19	132
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy	108
A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain‐like lesions: lights and shadows on the relationship with COVID‐19 infection	107
A distinctive skin rash associated with coronavirus disease 2019?	106
COVID‐19 and cutaneous manifestations: a systematic review	98
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials	97
Cutaneous manifestations in COVID‐19: the experiences of Barcelona and Rome	95
Cutaneous manifestations of SARS‐CoV‐2 infection: a clinical update	91
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis	89
Pityriasis rosea as a cutaneous manifestation of COVID‐19 infection	87
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion	86
Acute urticaria with pyrexia as the first manifestations of a COVID‐19 infection	84
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations	82

Clinical and biological impact of the exposome on the skin	82
Comment on ‘Cutaneous manifestations in COVID‐19: a first perspective’ by Recalcati S	81
Dermatologists and SARS‐CoV‐2: the impact of the pandemic on daily practice	80
European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II	77
Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel	75
European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology	74
Comment on: Cutaneous manifestations in COVID‐19: a first perspective. Safety concerns of clinical images and skin biopsies	74
European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations	68
2021 European guideline on the management of Mycoplasma genitalium infections	68
The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?	66
Erythema multiforme and Kawasaki disease associated with COVID‐19 infection in children	64
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study	64
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis	63
Lichen planus arising after COVID‐19 vaccination	63
Personal protective equipment induced facial dermatoses in healthcare workers managing Coronavirus disease 2019	63
2019 IUSTI‐Europe guideline for the management of anogenital warts	62
Skin reactions to non‐glove personal protective equipment: an emerging issue in the COVID‐19 pandemic	61
3D wide‐field multispectral photoacoustic imaging of human melanomas in vivo: a pilot study	60
Psoriasis exacerbation after COVID‐19 vaccination: a report of 14 cases from a single centre	60
Skin manifestations of the BNT162b2 mRNA COVID‐19 vaccine in healthcare workers. ‘COVID‐arm’: a clinical and histological characterization	60
UpdatedS2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)	59
Delayed melanoma diagnosis in the COVID‐19 era: increased breslow thickness in primary melanomas seen after the COVID‐19 lockdown	58
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled t	58
Transient cutaneous manifestations after administration of Pfizer‐BioNTech COVID‐19 Vaccine: an Italian single‐centre case series	56
Cutaneous manifestations in SARS‐CoV‐2 infection (COVID‐19): a French experience and a systematic review of the literature	55
The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis	55
SARS‐CoV‐2 infection presenting as a febrile rash	54
Line‐field confocal optical coherence tomography of basal cell carcinoma: a descriptive study	54
Common causes of hair loss – clinical manifestations, trichoscopy and therapy	54
European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I	53
Prevalence of most common skin diseases in Europe: a population‐based study	53
New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination	51
SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐23 inhibitor	51
Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic	51
Development of severe pemphigus vulgaris following SARS‐CoV‐2 vaccination with BNT162b2	51
Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic	51
Dermatology staff participate in fight against Covid‐19 in China	51
Cutaneous small vessel vasculitis secondary to COVID‐19 infection: a case report	50
Teledermatology for acne during COVID‐19: high patients’ satisfaction in spite of the emergency	50
Varicella‐zoster and herpes simplex virus reactivation post‐COVID‐19 vaccination: a review of 40 cases in an International Dermatology Registry	50
A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy	49
Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy	47
Are chilblain‐like acral skin lesions really indicative of COVID‐19? A prospective study and literature review	46
Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change	46
Antibiotic resistance in acne: changes, consequences and concerns	46
Invivo characterization of healthy human skin with a novel, non‐invasive imaging technique: line‐field confocal optical coherence tomography	45
SARS‐CoV‐2‐induced telogen effluvium: a multicentric study	45
European Task Force on Contact Dermatitis statement on coronavirus disease‐19 (COVID‐19) outbreak and the risk of adverse cutaneous reactions	45
Psoriasis flare‐up associated with second dose of Pfizer‐BioNTech BNT16B2b2 COVID‐19 mRNA vaccine	44
European dermatology forum – updated guidelines on the use of extracorporeal photopheresis 2020 – part 1	44

Safety of dupilumab in severe atopic dermatitis and infection of Covid‐19: two case reports	43
Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men	43
Prompt onset of Rowell's syndrome following the first BNT162b2 SARS‐CoV‐2 vaccination	43
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltI	42
Adult skin acute stress responses to short‐term environmental and internal aggression from exposome factors	42
Histologic features of long‐lasting chilblain‐like lesions in a paediatric COVID‐19 patient	42
Histology of skin lesions establishes that the vesicular rash associated with COVID‐19 is not ‘varicella‐like’	41
Cutaneous small‐vessel vasculitis associated with novel 2019 coronavirus SARS‐CoV‐2 infection (COVID‐19)	40
Global coronavirus pandemic (2019‐nCOV): implication for an Italian medium size dermatological clinic of a II level hospital	40
Monkeypox virus case with maculopapular exanthem and proctitis during the Spanish outbreak in 2022	40
Chronic nodular prurigo: clinical profile and burden. A European cross‐sectional study	38
Persistent maculopapular rash after the first dose of Pfizer‐BioNTech COVID‐19 vaccine	38
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD	38
Diversity of clinical appearance of cutaneous manifestations in the course of COVID‐19	37
Evolution of COVID‐19 infection in four psoriatic patients treated with biological drugs	37
Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus	37
Pityriasis rosea‐like eruptions following vaccination with BNT162b2 mRNA COVID‐19 Vaccine	37
Risk of tuberculosis reactivation during interleukin‐17 inhibitor therapy for psoriasis: a systematic review	36
Reply to “Psoriasis exacerbation after COVID‐19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al.	36
Protecting medical staff from skin injury/disease caused by personal protective equipment during epidemic period of COVID‐19: experience from China	36
Retiform purpura as a dermatological sign of coronavirus disease 2019 (COVID‐19) coagulopathy	36
Epidemiological and clinical aspects of Trichophyton mentagrophytes/Trichophyton interdigitale infections in the Zurich area: a retrospective study using genotyping	35
A generalized purpuric eruption with histopathologic features of leucocytoclastic vasculitis in a patient severely ill with COVID‐19	35
Skin cancer triage and management during COVID‐19 pandemic	35
Viral exanthem in COVID‐19, a clinical enigma with biological significance	35
Atypical erythema multiforme palmar plaques lesions due to Sars‐Cov‐2	34
Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real‐life experience	34
Skin adverse events related to personal protective equipment: a systematic review and meta‐analysis	34
Symmetric cutaneous vasculitis in COVID‐19 pneumonia	34
Iatrogenic dermatitis in times of COVID‐19: a pandemic within a pandemic	34
A clinicopathological study of eight patients with COVID‐19 pneumonia and a late‐onset exanthema	34
Stigma in visible skin diseases – a literature review and development of a conceptual model	34
Acro‐ischaemia in hospitalized COVID‐19 patients	34
Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?	33
Hyaluronic acid biomaterial for human tissue‐engineered skin substitutes: Preclinical comparative in vivo study of wound healing	33
SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor	33
Clinical and histological characterization of late appearance maculopapular eruptions in association with the coronavirus disease 2019. A case series of seven patients	33
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19	33
Estimated effect of COVID‐19 lockdown on melanoma thickness and prognosis: a rate of growth model	33
5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia	33
Did Whatsapp® reveal a new cutaneous COVID‐19 manifestation?	33
European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement	32
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis	32
Systemic therapies for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN‐based systematic review and meta‐analysis	32
Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID‐19 vaccine	32
Incidence of pemphigoid diseases in Northern Germany in 2016 – first data from the Schleswig‐Holstein Registry of Autoimmune Bullous Diseases	32
Cutaneous adverse events: a predictor of tumour response under anti‐PD‐1 therapy for metastatic melanoma, a cohort analysis of 189 patients	32
Is Scabies becoming less sensitive to permethrin therapy?	32
Urticarial vasculitis in COVID‐19 infection: a vasculopathy‐related symptom?	32
Cutaneous manifestation of COVID‐19 in images: a case report	32
Acute generalized exanthematous pustulosis with erythema multiforme‐like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID‐19)	32
A systematic review of worldwide data on tinea capitis: analysis of the last 20 years	32
Urticaria‐like lesions in COVID‐19 patients are not really urticaria – a case with clinicopathological correlation	31
Major cluster of paediatric ‘true’ primary chilblains during the COVID‐19 pandemic: a consequence of lifestyle changes due to lockdown	31
Performance of a deep neural network in teledermatology: a single‐centre prospective diagnostic study	31
Comorbidities in pediatric alopecia areata	31
Medical education and care in dermatology during the SARS‐CoV2 pandemia: challenges and chances	31
Histological pattern in COVID‐19‐induced viral rash	31
STIs and the COVID‐19 pandemic: the lockdown does not stop sexual infections	31
The red half‐moon nail sign: a novel manifestation of coronavirus infection	31
2021 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens	31
The broad spectrum of dermatological manifestations in COVID‐19: clinical and histopathological features learned from a series of 34 cases	31
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study	30
Occupational skin conditions on the front line: a survey among 484 Chinese healthcare professionals caring for Covid‐19 patients	30
Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling	30
New onset of mainly guttate psoriasis after COVID‐19 vaccination: a case report	30
Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVI	30
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial	30
Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting	30
Mass quarantine measures in the time of COVID‐19 pandemic: psychosocial implications for chronic skin conditions and a call for qualitative studies	30
S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)	30
Introductory histopathological findings may shed light on COVID‐19 paediatric hyperinflammatory shock syndrome	29
Epidermal thickness in healthy humans: a systematic review and meta‐analysis	29
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose	29
Development of oral lichen planus after COVID‐19 vaccination – a rare case report	29
Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19	28
Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review	28
Demodex: a skin resident in man and his best friend	28
COVID‐19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management	28
No evidence of increased risk for Coronavirus Disease 2019 (COVID‐19) in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area – Bergamo, Lombardy, Italy	28

A machine learning‐based, decision support, mobile phone application for diagnosis of common dermatological diseases	28
A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient‐Education Network in Dermatology (OPENED) task forc	28
BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2	28
Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy	27
Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options	27
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic	27
Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin	27
Concurrent chilblains and retinal vasculitis in a child with COVID‐19	27
Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase	27
2020 European guideline on the management of genital molluscum contagiosum	27
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b tri	27
Relapsing symmetric livedo reticularis in a patient with COVID‐19 infection	27
COVID‐19 and dermatology: a comprehensive guide for dermatologists	27
Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study	27
Personal solar ultraviolet radiation dosimetry in an occupational setting across Europe	26
Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome	26
De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort	26
Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA	26
Reply to ‘Cutaneous adverse effects of the available COVID‐19 vaccines in India: A questionnaire‐based study’ by Bawane J et al.	26
Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis	26
Improvement of SARS‐CoV‐2 symptoms following Guselkumab injection in a psoriatic patient	26
‘Occupational dermatoses from Personal Protective Equipment during the COVID‐19 pandemic in the tropics – A Review’	26
Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific	26
Atopic dermatitis exacerbation after Covid‐19 vaccination in Dupilumab‐treated patients	26
The top 100 most cited articles in rosacea: a bibliometric analysis	26
Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review	26
Real‐life effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study	26
Line‐field confocal optical coherence tomography of psoriasis, eczema and lichen planus: a case series with histopathological correlation	25
Androgen receptor genetic variant predicts COVID‐19 disease severity: a prospective longitudinal study of hospitalized COVID‐19 male patients	25
Psychosocial burden of Hidradenitis Suppurativa patients’ partners	25
Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA‐PSO: Belgian Evidence‐based	25
Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford–AstraZeneca COVID‐19 vaccine: report of three cases from India	25
Brodalumab for the treatment of moderate‐to‐severe plaque‐type psoriasis: a real‐life, retrospective 24‐week experience	25
Coronavirus 19 presenting with atypical Sweet's syndrome	25
Sexual impairment in patients with hidradenitis suppurativa: a systematic review	25
Face the COVID‐19 emergency: measures applied in an Italian Dermatologic Clinic	25
Incidence and risk factors for dupilumab associated ocular adverse events: a real‐life prospective study	25
Reply to ‘Development of severe pemphigus vulgaris following SARS‐CoV‐2 vaccination with BNT162b2’ by Solimani et al.	25
Validity of EQ‐5D‐5L, Skindex‐16, DLQI and DLQI‐R in patients with hidradenitis suppurativa	25
Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis	25
Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance	25
Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)	25
Continuous glucose monitoring systems give contact dermatitis in children and adults despite efforts of providing less ‘allergy‐ prone’ devices: investigation and advice hampered by insufficient mater	25
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study	25
Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases)	24
Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID‐19 vaccine: another piece of SARS‐CoV‐2 skin puzzle?	24
New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare‐up after Sars‐Cov‐2 vaccination	24
Urticaria (angioedema) and COVID‐19 infection	24
Intravenous allogeneic multilineage‐differentiating stress‐enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open‐label study	24
Diagnostic accuracy and interobserver concordance: teledermoscopy of 600 suspicious skin lesions in Southern Denmark	24
The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non‐lesional skin	24
European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2	24
Comparison of a 1064‐nm neodymium‐doped yttrium aluminum garnet picosecond laser using a diffractive optical element vs. a nonablative 1550‐nm erbium‐glass laser for the treatment of facial acne scarr	24
Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experience	23
Herpes Zoster following SARS‐CoV‐2 vaccination – a series of four cases	23
Real‐world evidence from over one million COVID‐19 vaccinations is consistent with reactivation of the varicella‐zoster virus	23
Expert consensus on the systemic treatment of atopic dermatitis in special populations	23
Teledermatology for COVID‐19 cutaneous lesions: substitute or supplement?	23
Systematic review of BRAF/MEK inhibitors‐induced Severe Cutaneous Adverse Reactions (SCARs)	23
Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic	23
Incidence of occupational contact dermatitis in healthcare workers: a systematic review	23
Nondermatophyte mould onychomycosis	23
Should SARS‐CoV‐2 influence immunosuppressive therapy for autoimmune blistering diseases?	22
Transition of cutaneous into systemic lupus erythematosus following adenoviral vector‐based SARS‐CoV‐2 vaccination	22
Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China	22
Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes	22
Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib	22
Vipera snakebite in Europe: a systematic review of a neglected disease	22
Prevalence and age distribution of pemphigus and pemphigoid diseases among paediatric patients in Germany	22
Recurrence of cutaneous T‐cell lymphoma post viral vector COVID‐19 vaccination	22
European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics	22
Art of performing dermoscopy during the times of coronavirus disease (COVID‐19): simple change in approach can save the day!	22
Retroauricular dermatitis with vehement use of ear loop face masks during COVID‐19 pandemic	22
Adverse skin reactions following different types of mask usage during the COVID‐19 pandemic	22
Mycosis fungoides: developments in incidence, treatment and survival	22
2019 novel coronavirus disease epidemic: skin protection for healthcare workers must not be ignored	22
Herpes zoster after ChAdOx1 nCoV‐19 vaccine: a case series	22
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – A network meta‐analysis	22
Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator‐blinded, randomized controlled trial	21
Sebocyte differentiation as a new target for acne therapy: an in vivo experience	21
A late‐onset widespread skin rash in a previous COVID‐19‐infected patient: viral or multidrug effect?	21
Real‐world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group	21
COVID vaccine‐induced lichen planus on areas previously affected by vitiligo	21
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab	21
Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany	21
Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAG	21
Complete blood collection‐based systemic inflammation biomarkers for patients with hidradenitis suppurativa	21
First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis	21
IgE autoantibodies in serum and skin of non‐bullous and bullous pemphigoid patients	21
Scabies outbreak during home confinement due to the SARS‐CoV‐2 pandemic	21
Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report	21
An unusual case of bullous haemorrhagic vasculitis in a COVID‐19 patient	21
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experience	20
Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa	20
Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature	20